Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer
Immune checkpoint inhibitors targeting PD-1 and PD-L1 have demonstrated anti-tumor activity in several advanced solid malignancies. In previously treated metastatic castration resistant prostate cancer (mCRPC), a small subset of patients have a therapeutic response to checkpoint inhibition. Those wh...
Main Authors: | Harry J. Han, Yun Rose Li, Mack Roach, Rahul Aggarwal |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-08-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920936084 |
Similar Items
-
Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
by: Matthew D. Tucker, et al.
Published: (2019-08-01) -
Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
by: Motohiro Fujiwara, et al.
Published: (2020-03-01) -
The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer
by: Jim N. Rose, et al.
Published: (2015-06-01) -
Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Iván Henríquez, et al.
Published: (2021-09-01) -
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
by: Dhruv Bansal, et al.
Published: (2021-01-01)